ImmunoGen Announces Initial Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status

• NASDAQ: $IMGN
• Notified: $4.08
• 17:02 EDT